Peptide-YY(3-36)/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries

OBJECTIVE: Obesity-linked type 2 diabetes (T2D) is a worldwide health concern and many novel approaches are being considered for its treatment and subsequent prevention of serious comorbidities. Co-administration of glucagon like peptide 1 (GLP-1) and peptide YY(3-36) (PYY(3-36)) renders a synergist...

Descripción completa

Detalles Bibliográficos
Autores principales: Boland, Brandon B., Laker, Rhianna C., O'Brien, Siobhan, Sitaula, Sadichha, Sermadiras, Isabelle, Nielsen, Jens Christian, Barkholt, Pernille, Roostalu, Urmas, Hecksher-Sørensen, Jacob, Sejthen, Sara Rubek, Thorbek, Ditte Dencker, Suckow, Arthur, Burmeister, Nicole, Oldham, Stephanie, Will, Sarah, Howard, Victor G., Gill, Benji M., Newton, Philip, Naylor, Jacqueline, Hornigold, David C., Austin, Jotham, Lantier, Louise, McGuinness, Owen P., Trevaskis, James L., Grimsby, Joseph S., Rhodes, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717237/
https://www.ncbi.nlm.nih.gov/pubmed/34781035
http://dx.doi.org/10.1016/j.molmet.2021.101392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717237/
https://www.ncbi.nlm.nih.gov/pubmed/34781035
http://dx.doi.org/10.1016/j.molmet.2021.101392

Ejemplares similares